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ABSTRACT
The effects of nicotine on the tail-flick and hot-plate tests were
determined to identify nicotinic receptor subtypes responsible for
spinally and supraspinally mediated nicotine analgesia in knockin
mice expressing hypersensitive 4 nicotinic receptors (L9S), in
seven inbred mouse strains (C57BL/6, DBA/2, A/2, CBA/2, BALB/
cByJ, C3H/HeJ, and 129/SvEv), and in two F1 hybrids (B6CBAF1
and B6D2F1). L9S heterozygotes were6-fold more sensitive to
the antinociceptive effects of nicotine than the wild-type controls
in the hot-plate test but not in the tail-flick assay. Large differences
in the effects of nicotine were also observed with both tests for the
seven mouse strains. A/J and 129 mice were 6- to 8-fold more
sensitive than CBA and BALB mice. In addition, B6CBAF1 hybrid
mice were even less sensitive than CBA mice. Nicotinic binding
sites weremeasured in three spinal cord regions and the hindbrain
of the inbred strains. Significant differences in cytisine-sensitive,
high affinity [125I]epibatidine binding site levels (42* subtypes),
but not in 125I--bungarotoxin binding (7* subtypes), were ob-
served. Significant negative correlations between cytisine-sensi-
tive [125I]epibatidine binding and nicotine ED50 for both tests were
noted. Our results indicate that 42* acetylcholine nicotinic re-
ceptors (nAChR) are important in mediating nicotine analgesia in
supraspinal responses, while also showing that 42*-nAChR and
at least one other nAChR subtype appear to modulate spinal
actions.
Findings that nicotine is an antinociceptive agent in ani-
mals (Aceto et al., 1986) and that cigarette smoking and
nicotine reduce pain in humans (Lane et al., 1995; Jammer et
al., 1998) suggest that nicotinic compounds may be useful in
the treatment of pain. Furthermore, the observation that the
nicotinic agonist epibatidine is 100 times more potent than
morphine as an analgesic in the tail-flick and hot-plate tests
(Badio and Daly, 1994) has spurred renewed interest in the
development of nicotinic agents as analgesics. Analgesic
drugs currently used produce serious side effects on long-
term use; safer and more efficacious analgesic agents are
needed. It is generally agreed that central pathways modu-
late the analgesic actions of nicotine (Sahley and Berntson,
1979); in particular, the spinal cord is a major site of action
for tail-flick nociception given that i.t. administration of nic-
otinic agonists produces antinociception in this test (Aceto et
al., 1986; Christensen and Smith, 1990). In addition, Cag-
giula et al. (1995) suggested that nicotine’s effects on the
tail-flick and hot-plate tests involve at least partially sepa-
rate pathways. Unfortunately, only limited progress has
been made toward identifying the neuronal nicotinic acetyl-
choline receptor (nAChR) subtypes expressed in spinal cord
that modulate pain, perhaps because mRNA for virtually all
the nAChR subtypes have been identified in dorsal root gan-
glion neurons of adult (Haberberger et al., 2004) and neona-
tal mice (Cordero-Erausquin et al., 2004). This complexity
may explain why studies using pharmacological approaches
to identify the nAChR subtypes that modulate the antinoci-
ceptive effects of nicotinic agonists (Damaj et al., 1998) and
antagonists (Iwamoto and Marion, 1993) are not in complete
agreement.
Studies using nAChR subunit null mutant (gene knockout)
mice have suggested roles for specific nAChR subtypes in
nicotine-induced antinociception. Mice lacking either the 4
or 2 nicotinic receptor subunit showed reduced sensitivity to
nicotine-induced antinociception in the hot-plate and tail-
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flick acute pain tests (Marubio et al., 1999). Both 4 and 2
null mutant mice failed to respond to nicotine on the hot-
plate test at doses that were fully efficacious in wild-type
(WT) mice, suggesting a prominent role for 42-nAChR. In
contrast, both 4 and 2 gene deletion resulted in only modest
(2–3-fold) reductions in agonist potency with the tail-flick
test.
The present study used two genetic approaches to investi-
gate which nAChR subtypes modulate the actions of nicotine
on the hot-plate and tail-flick tests. The first approach took
advantage of knockin mice that express mutated 4*-nAChR
(Labarca et al., 2001). These mice express 4 subunits with a
leucine to serine substitution in the 9 position (L9S) of the
pore-lining M2 region, which renders mice hypersensitive to
nicotine in functional and behavioral tests (Labarca et al.,
2001; Fonck et al., 2003). The second approach took advan-
tage of the findings that outbred and inbred mouse strains
differ in sensitivity to the effects of nicotine (Seale et al.,
1998) and epibatidine on thermal reactivity tests (Flores et
al., 1999), locomotor activity (Collins et al., 1988; Marks et
al., 1989a), hypothermia (Tritto et al., 2001), and seizures
(Miner and Collins, 1989). Mouse strains also differ in brain
[3H]nicotine (42*-nAChR) (Marks et al., 1989a) and
125I--
bungarotoxin (BTX) (7-nAChR) binding (Stitzel et al., 1998).
Moreover, strain variability in [3H]nicotine binding shows a
strong correlation with variations in nicotine-induced loco-
motor activity and changes in body temperature, whereas
variability in 125I--BTX binding correlates with the severity
of nicotine-induced seizures. Further nAChR subtype speci-
ficity can be achieved by measuring high affinity (KD  20
pM) radiolabeled epibatidine binding, which can be divided
into two major components based on the sensitivity to inhi-
bition by cytisine. The fraction sensitive to cytisine inhibition
is primarily composed of the 42 subtype, whereas cytisine-
resistant sites are thought to represent 32*, 34*, and
62* receptors (Marks et al., 2006). The observation that
strain variability in responses to nicotine is significantly
correlated with differences in binding of radioactive nicotinic
ligands prompted us to study the effects of nicotine on the
hot-plate and tail-flick tests of seven inbred mouse strains
known to be differentially sensitive to nicotine for other mea-
sures (Marks et al., 1989b), as well as for two F1 hybrids. We
then measured cytisine-sensitive and cytisine-resistant
[125I]epibatidine binding and 125I--BTX binding in hind-
brain and cervical, thoracic, and lumbar spinal cord of these
mouse strains.
Materials and Methods
Animals
Generation of the L9S strain, by replacing the native 4 subunit
of nAChR with a mutated form, was described previously (Labarca et
al., 2001). Only heterozygous L9S mice with an intact neomycin
resistance cassette were used because L9S homozygous mice are
neonatal-lethal; therefore, the L9S designation used throughout the
article refers to these heterozygotes. Male mice from the following
inbred strains were used: C57BL/6J, DBA/2JIbg, A/J, CBA/J, C3H/
HeJ, BALB/cByJ, 129/SvEv, B6CBAF1, and B6D2F1. DBA/2JIbg
mice were obtained from the breeding colony at the Institute for
Behavioral Genetics (Boulder, CO). The 129/SvEv strain was ob-
tained from Taconic (Germantown, NY). The remaining strains were
purchased from Jackson Laboratories (Bar Harbor, ME) and housed
in the mouse colony at the Institute for Behavioral Genetics for at
least 2 weeks before testing. Mice were housed in groups of three to
four per cage and had free access to food and water. All the animals
were 60 to 90 days of age at the time of testing. The study was
reviewed and approved by the Institutional Animal Care and Use
Committee of the Virginia Commonwealth University and the Ani-
mal Care and Utilization Committee of the University of Colorado.
Drugs
Mecamylamine hydrochloride was a gift from Merck Sharp and
Dohme (West Point, PA). Morphine sulfate and ()-nicotine were
obtained from Sigma-Aldrich (St. Louis, MO). All the drugs were
dissolved in physiological saline (0.9% sodium chloride), and all the
doses are expressed as the free base of the drug.
Antinociceptive Tests
Tail-Flick Test. Mice were lightly restrained by hand while a
radiant heat light source was shone onto the upper portion of the tail.
Latency to remove the tail from the heat source was recorded for
each animal. A control response (2–4-s latency) was determined for
each mouse before treatment, and test latency was determined after
drug administration. To minimize tissue damage, a maximal latency
of 10 s was imposed. Antinociceptive response was calculated as
percentage of maximal possible effect (%MPE), where %MPE {[test
value  baseline]/[cutoff time (10 s)  control value]}  100, where
baseline represents the value before nicotine. Groups of 8 to 12
animals were used for each dose and for each treatment. Mice were
tested 5 min after an s.c. injection of nicotine.
Hot-Plate Test. Mice were tested 2 h before and 5 min after an
s.c. injection of nicotine. The animals were placed on a 55°C platform
(Harvard Apparatus, Holliston, MA) and were observed until they
started to show pain-avoidance behavior, such as jumping or licking
of the paws. Animals that did not respond to the noxious heat
stimulus after 40 s were removed from the plate. Latency to pain
avoidance measured in seconds was used to calculate %MPE with
the following equation: {[test value  baseline]/[cutoff time (40 s) 
baseline]}  100. Baseline latency that lasted 8 to 12 s was assessed
with a saline injection.
To assess specificity of the nicotine-induced analgesia in L9S,
animals were injected with mecamylamine (1 mg/kg, s.c.) 5 min
before receiving a single nicotine injection in the hot-plate and tail-
flick tests. For comparison purposes, the specificity of nociceptive
responses in L9S mice was also evaluated by determining the po-
tency of morphine in the hot-plate and tail-flick tests. Animals were
tested 20 min after an s.c. injection of morphine.
Binding Experiments
Tissue Preparation. Mice were killed by cervical dislocation.
Their brains were removed and placed on ice, and the hindbrains
(pons medulla) were dissected. The spinal column was isolated and
divided into thoracic, cervical, and lumbar regions. Each segment of
the spinal cord was removed from the spinal column by gentle flush-
ing with ice-cold, isotonic saline. The dissected tissue was subse-
quently placed in hypotonic buffer (14 mM NaCl, 0.2 mM KCl, 0.2
mM CaCl2, 0.1 mM MgSO4, 2 mM HEPES, pH  7.5). Samples were
homogenized using a glass-Teflon tissue grinder. Homogenized sam-
ples were centrifuged at 10,000g for 20 min, and the supernatant
was discarded. The pellet was resuspended in hypotonic buffer and
centrifuged again at 10,000g for 20 min. This procedure was re-
peated two more times. The final washed pellet was resuspended in
dilute buffer to a concentration of 1 to 2 mg/ml protein.
[125I]Epibatidine Binding. [125I]Epibatidine (specific activity 
2200 Ci/mmol; PerkinElmer Life and Analytical Sciences, Boston,
MA) binding was conducted essentially as described previously
(Marks et al., 1998). Samples were incubated for 3 h in 30 l of buffer
(135 mM NaCl, 2 mM KCl, 2 mM CaCl2, 1 mMMgSO4, 0.02% bovine
serum albumin at 20°C, 25 mM HEPES, pH  7.5) using a final
[125I]epibatidine concentration of 400 pM. Cytisine-resistant binding
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was initially measured by constructing inhibition curves for cytisine
(cytisine concentrations from 1  109 to 5  105 M) for two mice
of each strain. Subsequently, cytisine-resistant sites were calculated
from data obtained for binding in the presence of 0, 50, and 150 nM
cytisine. Blanks were established using 0.1 mM nicotine. Blanks
represented less than 5% of specific binding. Following the incuba-
tion, samples were filtered using an Inotech Biosystems (Rockville,
MD) harvester and two layers of glass fiber filter [top filter MFS GC,
bottom filter Gelman (Ann Arbor, MI) A/E, both of which had been
soaked in 0.1% polyethylenimine]. Samples were washed six times
with ice-cold buffer without serum albumin. Samples were counted
using a Packard Tri-Carb liquid scintillation spectrometer
(PerkinElmer Life and Analytical Sciences) at 45% efficiency after
the addition of 1.5 ml of Budget Solve scintillation mixture (Sigma/
RBI, Natick, MA).
125I--BTX Binding. 125I--BTX (specific activity 200 Ci/mmol;
NEN) binding was essentially measured as described previously
(Marks et al., 1986b). Samples were incubated for 3 h in 100 l of
buffer (135 mM NaCl, 2 mM KCl, 2 mM CaCl2, 1 mM MgSO4, 0.02%
bovine serum albumin at 20°C, 25 mM HEPES, pH  7.5) using a
final 125I--BTX concentration of 1 nM. Blanks were determined by
including 1 mM nicotine in the incubations. Blanks represented
approximately 50% of specific binding at this concentration of [125I]-
BTX. Although maximal binding is not measured at this concentra-
tion, use of higher ligand concentrations resulted in very unfavorable
signal/noise ratios. After the incubation, samples were filtered using
an Inotech harvester and two layers of glass fiber filter (top filter
MFS GC, bottom filter Gelman A/E, both of which had been soaked
in 0.1% polyethylenimine). Samples were washed six times with
ice-cold buffer without serum albumin. Samples were counted using
a Packard gamma counter (PerkinElmer Life and Analytical Sci-
ences) at 80% efficiency.
Protein. Protein was measured with the method of Lowry et al.,
(1951) using bovine serum albumin as the standard.
Statistical Analysis
Statistical analysis of all the behavioral studies was performed
using either a t test or analysis of variance with a Dunnett’s post hoc
t test when appropriate. All the differences were considered signifi-
cant at p  0.05. ED50 values with a 95% confidence level (CL) for
behavioral data were calculated by unweighted least-squares linear
regression as described by Tallarida and Murray (1987). One-way
analysis of variance followed by Dunnett’s post hoc t test was used to
evaluate differences in binding in each tissue for each binding site.
Relationships among the parameters were assessed by linear regres-
sion.
Results
Antinociceptive Effects of Nicotine in the 4 L9S Mice
Antinociceptive effects of nicotine on L9S heterozygous
and WTmice in the tail-flick and hot-plate tests are shown in
Fig. 1, A and B. The latency response of noninjected control
mice to a painful stimulus did not differ significantly between
WT and L9S animals in either test, indicating that the
endogenous activation of the 4-nAChR subunit, even with a
Fig. 1. Dose-response curves of nicotine and morphine-
induced antinociception in L9S heterozygote (dark gray
circles) and WT (black circles) mice. Animals were tested in
the hot-plate and the tail-flick apparatus as described un-
der Materials and Methods. Animals were tested 5 min
after an s.c. nicotine injection in the tail-flick (A) and
hot-plate (B) tests. Each data point is the mean  S.E. of
n  6 to 8 animals. A different set of animals was tested 20
min after an s.c. morphine injection in the tail-flick (C) and
hot-plate (D) tests. Each data point is the mean S.E., n
6 to 8.
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mutation conferring hypersensitivity, is not essential to the
perception of acute thermal nociception.
The tail-flick test revealed no obvious hypersensitivity to
nicotine in the L9S mice (Fig. 1A) after s.c. injection of
various doses of nicotine. However, it should be noted that
doses higher than 0.5 mg/kg were not tested in L9S mice
because animals displayed tremors, shaking, and stereotypy
when higher doses of nicotine were administered (Fonck et
al., 2003). These behavioral responses in L9S mice are
thought to precede seizures, which are probably initiated in
subcortical structures such as the hippocampus, thalamus, or
medial habenula and are not thought to be directly involved
in antinociceptive responses. WT mice exhibited a dose-de-
pendent antinociception following nicotine administration at
doses greater than 0.5 mg/kg. In the hot-plate test (Fig. 1C),
WT mice showed a dose-dependent antinociceptive response
with an ED50 ( CL)  0.92 (0.7–1.1) mg/kg. In L9S mice,
the nicotine dose-response relation was shifted to the left
with an ED50 value of 0.17 (0.1–0.2) mg/kg (Fig. 1C). Thus, a
6-fold shift in the dose-response relation for nicotine-induced
antinociception was observed between L9S and WT mice.
The nicotinic receptor antagonist mecamylamine (1 mg/kg)
effectively blocked nicotine-induced analgesia described in
these experiments. Mecamylamine blocked the nicotine-in-
duced decrease in hot-plate nociception (data not shown) in
both L9S and WT animals. Mecamylamine also blocked the
nicotine-induced delay in tail-flick responses in WT mice.
Antinociceptive effects of morphine in the hot-plate and
tail-flick tests are shown in Fig. 1, B and D. L9S and WT
mice had similar dose-dependent antinociceptive responses
to morphine in the hot-plate test (Fig. 1D), yielding ED50
values of 6.8 (5.8–7.9) and 5.9 (4.8–7.1) mg/kg, respectively.
Similar potency for morphine was also observed for L9S and
WT mice in the tail-flick (Fig. 1B) test, with ED50 values of
0.90 (0.5–1.6) and 0.85 (0.4–1.8) mg/kg, respectively.
Antinociceptive Effects of Nicotine in Seven Inbred
Mouse Strains
Tail-Flick Test.No differences among the strains in basal
latencies for the tail-flick test were noted following saline
injection (latencies range, 1.7–2.4 s).
The effects of nicotine administration on the tail-flick re-
sponse of the seven inbred strains of mice are shown in Fig.
2, A and B, and the ED50 values calculated from these curves
are shown in Fig. 2C. Antinociceptive effects of nicotine dif-
fered significantly among the inbred strains. The dose-re-
sponse curves for nicotine-induced antinociception for mice of
the A/J and 129SvEv strains were similar and yielded similar
ED50 values [ED50 (95% CL), 0.48 (0.34–0.67) and 0.62
(0.05–0.70) mg/kg, respectively]. Dose-response curves of nic-
otine-induced antinociception for C57BL/6 and DBA/2 were
also similar, but these mice were less sensitive to nicotine
than either the A or 129 mice [ED50 (95% CL), 1.07 (0.97–
1.22) for C57BL/6 and 1.20 (0.94–1.60) mg/kg for DBA]. C3H
[ED50 (95% CL), 1.97 (1.4–2.6)] and BALB [ED50 (95% CL),
3.2 (2.6–3.8)] required significantly higher nicotine doses.
Antinociceptive effects of nicotine in CBA mice were also
small. Even at the highest dose of nicotine tested (2 mg/kg,
s.c.), the effect (16% MPE) was not significantly different
from saline control. Higher doses of nicotine (	2 mg/kg) were
not tested because of the increased risk of triggering seizures.
The rank order of the strains for sensitivity to the antinoci-
ceptive effects of nicotine measured by tail-flick was 129 
A/J	 C57BL/6 DBA/2	 C3H	 BALB CBA. Mice of the
129 strain were at least 4-fold more sensitive than those of
the CBA strain and 6-fold more sensitive than those of the
BALB strain.
Antinociceptive effects were also measured with two F1
hybrids. The B6D2F1 (F1 cross of C57BL/6 and DBA/2) were
more sensitive to nicotine [ED50 (95% CL), 0.68 (0.2–1.1)
mg/kg] than the parental strains, whereas B6CBAF1 (F1
Fig. 2. Antinociceptive effects of nico-
tine in seven inbred mice strains and
two F1 hybrids measured using the
tail-flick and hot-plate tests. Effects of
nicotine were measured in inbred
A/J (open circles), C57BL/6 (black
squares), DBA (light gray upright tri-
angles), 129 (dark gray diamonds),
BALB (white squares), C3H (dark
gray inverted triangles), and CBA
(dark gray circles) mice and in hybrid
B6CBAF1 (dark gray hexagons) and
B6D2F1 (light gray diamonds) mice
after s.c. administration of the indi-
cated doses of the drug. Mice were
tested 5 min after injection. Each
point represents the mean S.E., n
8 to 12 mice. Dose-response curves for
nicotine effects on tail-flick test are
shown in A and B, and ED50 values
calculated from these curves are
shown in C. Dose-response curves for
nicotine effects on hot-plate test are
shown in D and E, and ED50 values
calculated from these curves are
shown in F.
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cross of C57BL/6 and CBA) were significantly less sensitive
than either parent (1% MPE after a dose of 3.5 mg/kg).
Hot-Plate Test. Significant strain differences in baseline
responsiveness in the hot-plate test were observed (latencies
range, 5.5–9.7 s) [F(6,90)  5.8, p  0.05]. These differences
were not unexpected because strain differences in baseline
responsiveness have previously been noted for this test in
inbred mouse strains (Flores et al., 1999).
Dose-response curves for the antinociceptive effects of nic-
otine measured with the hot-plate test are shown in Fig. 2, D
and E, and ED50 values calculated from these curves are
shown in Fig. 2F. Similar to the results of the tail-flick test,
the potency of nicotine as an antinociceptive agent differed
significantly among the strains. In general, ED50 values were
lower for the hot-plate test than for the tail-flick test. A/J
mice were the most sensitive [ED50 (95% CL), 0.2 (0.16–0.24)
mg/kg]. 129SvEv mice were also quite sensitive [ED50 (95%
CL), 0.45 (0.41–0.49) mg/kg]. DBA/2 and C57BL/6 mice dis-
played similar responsiveness to nicotine [ED50 (95% CL),
0.85 (0.5–1.2) and 0.92 (0.73–1.2) mg/kg, respectively],
whereas C3H mice were slightly less sensitive [ED50 (95%
CL), 1.05 (0.8–1.3) mg/kg]. The BALB [ED50 (95% CL), 1.3
(0.97–1.8) mg/kg] and CBA [ED50 (95% CL), 1.55 (1.2–1.85)
mg/kg] mice required higher nicotine doses for antinocicep-
tion. In contrast to the tail-flick test, nicotine-mediated an-
tinociception was measurable in CBA mice in the hot-plate
test, but the ED50 value for CBA was the highest of the seven
strains tested [ED50 (95% CL), 1.55 (1.2–1.85) mg/kg]. Thus,
the rank order for sensitivity to nicotine-induced antinocicep-
tion for the hot-plate test was A/J 	 129 	 DBA/2  C57BL/
6 	 C3H 	 BALB 	 CBA. The ED50 value for CBA mice was
approximately 7.5-fold higher than that for A/J mice.
Antinociceptive effects were also measured with two F1
hybrids. As was the case with the tail-flick test, the B6D2F1
(F1 cross of C57BL/6 and DBA/2) were slightly more sensitive
to nicotine [ED50 (95% CL), 0.68 (0.2–1.1) mg/kg] than the
parental strains, whereas B6CBAF1 (F1 cross of C57BL/6
and CBA) were significantly less sensitive than either parent
(40%MPE after a dose of 3.5 mg/kg).
Receptor Determinations in Seven Inbred Mouse Strains
The density of three nicotinic binding sites was measured
to explore possible relationships between nAChR levels and
sensitivity to nicotine in the mouse strains studied. Binding
was measured in hindbrain and the cervical, thoracic, and
lumbar regions of spinal cord. The three binding sites mea-
sured were 125I--BTX (measuring 7-nAChR), cytisine-sen-
sitive [125I]epibatidine (measuring 2*-nAChR, primarily
42*-nAChR), and cytisine-resistant [
125I]epibatidine [mea-
suring a mixed population of 2*-nAChR (non–42*-nAChR)
and 4*-nAChR] (Marks et al., 2006).
Cytisine-Sensitive [125I]Epibatidine Binding. The
density of high-affinity [125I]epibatidine binding sites
sensitive to inhibition by cytisine was measured using a
[125I]epibatidine concentration of 400 pM. This concentration
is saturating, thereby providing a measurement of maximal
binding site density. Results for these measurements are
shown in Fig. 3.
Significant differences in binding site density among the
seven strains were observed [hindbrain, F(6,44)  2.34, p 
0.05; thoracic spinal cord, F(6,44)  2.84, p  0.05; and
lumbar spinal cord, F(6,44)  2.37, p  0.05; however, cer-
vical spinal cord was not significant, F(6,44)  2.01, p 	
0.05]. In every sample prepared, tissue prepared from A/J
mice had the highest densities. Binding for A/J mice was
significantly higher than that for CBA and C3Hmice in every
region. Relative binding site densities measured for tissue
obtained from DBA/2 and C57BL/6 mice were similar to each
Fig. 3. Cytisine-sensitive, high affin-
ity [125I]epibatidine binding. The den-
sity of cytisine-sensitive high affinity
[125I]epibatidine binding sites in the
hindbrain and cervical, thoracic, and
lumbar regions of the spinal cord was
measured using 400 pM ligand in
membranes prepared from each of the
seven different inbred mouse strains
and the two F1 hybrids as described
under Materials and Methods. Re-
sults are expressed in fmol/mg pro-
tein  S.E. for preparations from five
mice of each strain.
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other and varied among the regions. Binding for these two
strains was relatively high in hindbrain and cervical and
thoracic spinal cord, similar in magnitude to that of the A/J
mice.
Cytisine-sensitive [125I]epibatidine measured in hindbrain
and cervical spinal cord for the B6CBAF1 mice was interme-
diate between that of the two parental strains, whereas that
measured in thoracic spinal cord resembled that of the CBA
parent (lower than midpoint), and that in the lumbar spinal
cord was lower than that for either parent. A similar pattern
was also observed for the B6D2F1 mice, although binding in
both thoracic and lumbar spinal cord was lower than that of
either parent.
Cytisine-Resistant [125I]Epibatidine Binding. The
density of high affinity [125I]epibatidine binding sites was
calculated from binding using a saturating concentration of
400 pM [125I]epibatidine in the presence of 0, 50, and 150 nM
cytisine (Marks et al., 1998). Results for these measurements
are shown in Fig. 4.
The cytisine-resistant component of the high affinity
[125I]epibatidine binding represented a relatively small frac-
tion of total high affinity binding (20% in hindbrain, 15%
in the spinal cord). Whereas no significant differences in the
number of these binding sites among the strains were de-
tected in hindbrain, cervical spinal cord, or lumbar spinal
cord, significant differences among the strains were noted for
thoracic spinal cord [F(6,44)  2.82, p  0.05] with samples
prepared from A/J mice exhibiting higher binding than those
prepared from DBA/2, BALB, C3H, and 129 mice.
125I--BTX Binding. The density of 125I--BTX binding
sites was measured using a ligand concentration of 1 nM,
which is near the KD. Therefore, these measurements do not
represent maximal site densities. Results for 125I--BTX
binding in the four regions of all the inbred strains are shown
in Fig. 5. No significant differences in 125I--BTX binding
were observed for hindbrain or any area of the spinal cord.
Relationship between Nicotinic Binding Sites and
Antinociception
Because both the potency of nicotine’s antinociceptive ef-
fects and the density of nicotinic binding sites have been
measured in each of the seven inbred strains, linear regres-
sion analyses were conducted to compare the various mea-
sures. Scattergrams comparing the ED50 values for nicotine-
induced antinociception and density of cytisine-sensitive
[125I]epibatidine binding sites, cytisine-resistant [125I]epiba-
tidine binding sites, and [125I]-BTX binding sites in hind-
brain are shown in Fig. 6. ED50 values for the two thermal
pain tests for the seven inbred mouse strains were very
highly correlated (Fig. 6A, r  0.92). Highly significant
(p  0.01) correlations between ED50 for tail-flick (Fig. 6E,
r  0.89) and hot-plate (Fig. 6B, r  0.85) tests and the
density of cytisine-sensitive [125I]epibatidine binding sites
were also observed. No significant correlations between the
other two binding sites and the pain tests or among the three
binding sites were noted. Correlations between the density of
cytisine-sensitive [125I]epibatidine binding sites in cervical,
thoracic, or lumbar spinal cord and the ED50 values for the
hot-plate tests were not so robust (r  0.62, p  0.06) as
those for binding sites in hindbrain.
Discussion
Nicotinic agonists elicit antinociceptive responses in sev-
eral acute pain tests, including tail-flick and hot-plate tests.
Responses to the hot-plate are thought to be centrally medi-
ated, whereas the tail-flick is considered a spinal reflex (Cag-
giula et al., 1995). This study takes advantage of the rare
Fig. 4. Cytisine-resistant, high affin-
ity [125I]epibatidine binding. The den-
sity of cytisine-resistant high affinity
[125I]epibatidine binding sites in the
hindbrain and cervical, thoracic, and
lumbar regions of the spinal cord was
measured using 400 pM ligand in
membranes prepared from the seven
different inbred mouse strains and
the two F1 hybrids as described under
Materials and Methods. Results are
expressed in femtomole/milligram
protein  S.E. for preparations from
five mice of each strain.
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opportunity to study a behavioral test by exploiting both
specific targeted mutations in a candidate molecule and in-
bred strains that differ in many more genes. The studies
reported here further tested the postulate that activation of
42*-nAChR evokes the antinociceptive effects of nicotine
on the hot-plate and tail-flick tests.
Previous data based on gene knockouts (Marubio et al.,
1999) and antisense-mediated knockdown (Bitner et al.,
2000) indicate that 4* and 2* receptors are necessary for a
major antinociceptive component as measured in the hot-
plate test; however, the present finding that L9S mice,
which express a hypersensitive 4 receptor, are much more
sensitive to the effects of nicotine in the hot-plate test than
are the controls shows that nicotine activation of 4* recep-
tors in mice is sufficient to produce such antinociception.
Thus, the combination of necessity and sufficiency does pro-
vide compelling indications that, among the set of nAChR
receptor subtypes, 42*-nAChR dominate nicotine’s actions
on the hot-plate test.
Marubio et al. (1999) observed that 4 and 2 null mutant
mice were 2- to 3-fold less sensitive to nicotine than WT mice
on the tail-flick test and concluded that the effects of nicotine
on this test are modulated by the 42*-nAChR subtype plus
another, lower affinity nAChR. We did not detect an increase
in sensitivity to nicotine’s analgesic effects on the tail-flick
test in L9S mice. However, L9S could not be tested with the
full range of nicotine doses. The highest dose that was tested
(0.5 mg/kg) produced no measurable change in response in
either WT or mutant mice. The higher doses (1.0 and 2.0
mg/kg), which elicited effects in WT mice, were not used in
L9S mice because doses that exceed 0.5 mg/kg elicit tremors,
shaking, stereotypy, and convulsions in these mice (Fonck et
al., 2003). Thus, the data obtained with the L9S mutant
mice support the assertion that 42*-nAChR play a more
dominant role in regulating nicotine’s effects on the hot-plate
test than for the tail-flick response.
Studies with both knockout and knockin mice provide valu-
able insights into the role of 4*-nAChR in painmodulation, but
adaptive changes elicited by these mutations could affect the
nociceptive phenotype. For example, the number of dopamine
neurons in the substantia nigra is reduced by 35% in adult
L9S mice (Orb et al., 2004), and 4 null mutant mice exhibit
alterations in arborization of the dendrites of dopamine neurons
(Parish et al., 2005). These concerns prompted us to evaluate
the effects of nicotine in seven inbred mouse strains to evaluate
the variation in nicotine-induced antinociception.
Inbred mouse strains also vary substantially in sensitivity to
nicotine, as measured by a battery of behavioral tests, and the
seven inbred strains selected for the current study represent a
wide range of sensitivity to nicotine (Marks et al., 1989a). The
seven strains tested also differed markedly in sensitivity to the
effects of nicotine in both the hot-plate and tail-flick tests.
Indeed, the 7.5-fold difference in sensitivity to nicotine’s effects
on the hot-plate test between the most sensitive (A/J) and the
least sensitive (CBA) inbred strains was as great as the differ-
ence between the L9S mice and their WT littermates. These
results are consistent with the finding that inbred mouse
strains exhibit a 4-fold variation in sensitivity to epibatidine-
induced antinociception for the tail-immersion withdrawal
thermal assay, with the A/J strain being the most sensitive
(Flores et al., 1999).
The rank orders of ED50 values for the strains tested on the
hot-plate (A/J 	 129 	 DBA/2  C57BL/6 	 C3H 	 BALB 	
CBA) and tail-flick (129 A/J	 C57BL/6 DBA/2	 C3H	
BALB  CBA) tests are very similar (correlation coefficient
for ED50 values  0.94) but not identical, inasmuch as the
ED50 values for the hot-plate test tend to be lower than those
for the tail-flick test. One possible explanation for these find-
Fig. 5. 125I--BTX binding. The den-
sity of 125I--BTX binding sites in the
hindbrain and cervical, thoracic, and
lumbar regions of the spinal cord was
measured using 1 nM ligand in mem-
branes prepared from the seven dif-
ferent inbred and two hybrid mouse
strains as described under Materials
and Methods. Results are expressed
in fmol/mg protein  S.E. for prepa-
rations from five mice of each strain.
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ings is that 42*-nAChR dominate the effects of nicotine on
the hot-plate test, whereas an additional, lower affinity
nAChR contributes to the response in the tail-flick test. In-
deed, 7-selective antagonists (-BTX and methyllycaconi-
tine) and partial agonists (dimethoxybenzylidine anabaseine,
4-OH-DMXB) blocked the antinociceptive effects of choline
(an 7 agonist) on the tail-flick test (Damaj et al., 2000).
These results suggest that the 7-nAChR may be the lower
affinity receptor that also modulates the tail-flick test.
Inbred strain differences in drug sensitivity could be attrib-
uted to pharmacodynamic or pharmacokinetic differences. Nic-
otinemetabolism and elimination do not differ among several of
these inbred strains (Petersen et al., 1984). Therefore, it is
reasonable to assume that the pharmacogenetic variability ob-
served in our studies is caused by differences in nicotinic recep-
tors or any of the various downstream mechanisms engaged by
these receptors. In particular, although the L9S mice have a
subset of 4* receptors that bear a mutation conferring a dif-
ference in acetylcholine (ACh) sensitivity, it seems possible that
overall ACh sensitivity can also be governed by straightforward
differences in the number of receptors. Inbred mouse strains
differ in the number of brain nAChR, as measured by high
affinity [3H]nicotine (42*) and
125I--BTX (7) binding
(Marks et al., 1989a). Indeed, differences in binding site density
are significantly correlated with differences in effects of nicotine
on maze activities and hypothermia (Marks et al., 1989b).
These results prompted us to examine the potential associa-
tions between nicotine-induced antinociception and brainstem/
spinal cord nAChR numbers.
We measured nAChR binding in the spinal cord and the
hindbrain using [125I]epibatidine and 125I--BTX as ligands.
The high affinity epibatidine binding that is sensitive to
cytisine inhibition measures 42*-nAChR (Marks et al.,
2006). Strain differences in cytisine-sensitive [125I]epibati-
dine binding sites were seen in hindbrain and cervical, tho-
racic, and lumbar regions of spinal cord. Regression analysis
indicated a highly significant inverse correlation between
cytisine-sensitive [125I]epibatidine binding and ED[50 values
for both tail-flick (r  0.89) and hot-plate (r  0.85) tests.
This result and the fact that similar, but less robust, corre-
lations were found between binding site densities in spinal
cord and ED50 values (r  0.65) indicate that mice express-
ing higher 42*-nAChR levels are more responsive to nico-
tine-mediated antinociception. These correlations between
nicotinic analgesia and 42-nAChR binding sites are similar
to those obtained for other nicotine-mediated behavioral re-
sponses such as hypolocomotion and hypothermia (Marks et
al., 1989a). It is also likely that nicotine-evoked responses in
these complex behavioral assays depend on downstream
events not directly related to receptor levels. Such a possibil-
ity is reinforced by the results with the F1 hybrids, where the
B6CBAF1 showed striking overdominance toward resistance
to nicotine, whereas the B6D2F1 showed modest dominance
toward sensitivity. Such complex inheritance patterns for
nicotine-mediated behavioral responses have been observed
for both nicotine-induced locomotor (Marks et al., 1986a) and
hypothermic (Marks et al., 1984) responses.
nAChR are known to mediate release of several neurotrans-
Fig. 6. Correlations among ED50 val-
ues for hot-plate and tail-flick tests
and nicotinic binding sites in hind-
brain. Each point represents the
mean S.E.M. for the indicated value
for the seven inbred strains. Correla-
tion coefficients for each panel are
listed in the parentheses. Regression
lines are shown for correlations that
are statistically significant (p  0.05).
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mitters and neuropeptides such as ACh, serotonin, and norepi-
nephrine (Wonnacott et al., 1996); thus, differences in these
parameters could contribute to the strain difference observed.
Alternatively, activation of the endogenous opiate system may
occur downstream from 42*-nAChR. Many studies have ad-
dressed the question of whether nicotinic agonists elicit their
antinociceptive effects via interaction with endogenous opiate
systems. There is substantial evidence that nicotinic agonists
increase release of endogenous opiates and increase their syn-
thesis in the brain (Houdi et al., 1998). The findings that pre-
treatment with opiate antagonists inhibits the antinociceptive
effects of nicotine in rats (Biala et al., 2005) and mice (Berren-
dero et al., 2002), as well as the observation that preproen-
kephalin knockout mice exhibit decreased sensitivity to nico-
tine’s effects on tail-immersion and hot-plate tests (Berrendero
et al., 2005), suggest that nicotinic agonists exert some of their
analgesic effects via endogenous opiate release. However, we
did not find any change in sensitivity to the effects of morphine
on either the hot-plate or tail-flick tests in L9S mutant mice.
Likewise, 4 knockout mice did not show a detectable change in
sensitivity to the effects of morphine on the hot-plate and tail-
flick tests (Marubio et al., 1999). These findings argue that
opiate analgesia does not require direct activation of 4*-nico-
tinic receptors.
In summary, the studies reported here provide a new dimen-
sion that complements the conclusions drawn from the 4
and 2 knockout studies (Marubio et al., 1999). Taken together,
studies using knockout, gain-of-function, and inbred mouse
strain indicate that within the set of nAChR subtypes, activa-
tion of 42*-nAChR is both necessary and sufficient for nico-
tine-evoked antinociception in the hot-plate test. In contrast,
the 42*-nAChR and at least one other nAChR subtype regu-
late the effects of nicotine in the tail-flick test. The inbred strain
studies also indicate a role for 42-nAChR, but they also
clearly illustrate that factors downstream from nAChR activa-
tion influence responses to nicotine. Future studies with inbred
strains and their hybridsmay provide a basis for further genetic
analysis and could be useful for identifying the gene(s) that
influence variability of nicotinic receptor-mediated analgesic
mechanisms.
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